26. (canceled)

27. The method of claim **24**, wherein said oxidized amino acid residue is histidine.

28. The method of claim **24**, wherein said oxidized amino acid residue is tryptophan.

29. The method of claim **24**, wherein said aflibercept variant is selected from an amino acid residue on a polypeptide having an amino acid sequence as set forth in the group consisting of: SEQ ID NO.: 17, SEQ ID NO.: 18, SEQ ID NO.: 19, SEQ ID NO.: 20, SEQ ID NO.: 21, SEQ ID NO.: 22, SEQ ID NO.: 23, SEQ ID NO.: 56, SEQ ID NO.: 64, SEQ ID NO.: 65, SEQ ID NO.: 66, SEQ ID NO.: 67, SEQ ID NO.: 68, SEQ ID NO.: 69, SEQ ID NO.: 70, SEQ ID NO.: 71, and combinations thereof.

30. The method of claim **24**, further subjecting said protein sample of step (b) to one or more additional chromatographic steps selected from the group consisting of: cation exchange chromatography, hydrophobic interactive chromatography, size exclusion chromatography and a combination thereof.

31. The method of claim **19**, wherein said oxidized amino acid residue is histidine.

32. The method of claim **19**, wherein said oxidized amino acid residue is tryptophan.

33. The method of claim **19**, wherein said cell is selected from the group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

34. The method of claim **19**, further subjecting said protein sample of step (b) to one or more additional chromatographic steps selected from the group consisting of: cation exchange chromatography (CEX), hydrophobic interactive chromatography, size exclusion chromatography and a combination thereof.

* * * * *